Key facts
- It has raised $177.6M; the latest was IPO in Nov 2025.
- Notable investors include Tailong VC, Hangzhou Capital, Honghui Capital, LYFE Capital, CMS Ventures — 9 tracked in total.
- Status: In IPO Registration.
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Winhealth Pharma
- ·The full record, as it builds
Funding rounds
No funding rounds for Winhealth Pharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Winhealth Pharma
Operator of a Hong Kong-based pharmaceutical contract sales organization (CSO) intended to introduce leading healthcare products and technologies from all over the world into Chinese market. The company establishes long-term strategic partnership with well-known global and domestic pharmaceutical companies to cover a broad therapeutic area, providing more resources and advanced treatment facilities to the medical community and patients.
- Sector
- Business Products and Services (B2B)
- HQ
- Hong Kong, Hong Kong
- Founded
- 1992
- Employees
- 790
- Website
- en.winhealth.hk/
- Ownership
- In IPO Registration
Winhealth Pharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Winhealth Pharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Winhealth Pharma in its N-PORT filings yet. We sweep new filings monthly.